Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • NEWS AND VIEWS

Stomach cancer gets a triple punch of therapy

Harnessing immune cells to target tumours is a growing trend. The results of a clinical trial combining such treatment with other standard therapies for gastric cancer have altered medical practice — and more changes are to come.
  1. Myriam Chalabi

    1. Myriam Chalabi is in the Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam 90203, the Netherlands.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Gastric cancer is a highly aggressive disease. Writing in Nature, Janjigian et al.1 present clinical data that point to a way to improve outcomes for people who have this type of tumour.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 600, 608-609 (2021)

doi: https://doi.org/10.1038/d41586-021-03458-7

References

  1. Janjigian, Y. Y. et al. Nature 600, 727–730 (2021).

    Article  Google Scholar 

  2. Janjigian, Y. Y. et al. Lancet 398, 27–40 (2021).

    Article  PubMed  Google Scholar 

  3. Baselga, J. et al. J. Clin. Oncol. 14, 737–744 (1996).

    Article  PubMed  Google Scholar 

  4. Slamon, D. J. et al. N. Engl. J. Med. 344, 783–792 (2001).

    Article  PubMed  Google Scholar 

  5. Bang, Y.-J. et al. Lancet 376, 687–697 (2010).

    Article  PubMed  Google Scholar 

  6. Gall, V. A. et al. Cancer Res. 77, 5374–5383 (2017).

    Article  PubMed  Google Scholar 

  7. Shitara, K. et al. N. Engl. J. Med. 382, 2419–2430 (2020).

    Article  PubMed  Google Scholar 

Download references

Competing Interests

The author’s institute receives research funding from Roche-Genentech, Bristol-Myers Squibb and Merck, Sharp & Dohme.

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links